Molecular pathology of early stage chemically induced hepatocarcinogenesis

Pathology International

Volumn 59, Issue 9, 2009, Pages 605-622

  Ogawa, Katsuhiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Hepatocarcinogenesis; Isolation; Preneoplastic hepatocytes; Selection; Transformation

Indexed keywords

BETA CATENIN; CANCER GROWTH FACTOR; CARCINOGEN; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOXIDE HYDROLASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE 6 PHOSPHATASE; GLYCOGEN PHOSPHORYLASE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; SOMATOMEDIN B; STAT3 PROTEIN;

CELL AGING; CELL CYCLE REGULATION; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CHEMICAL CARCINOGENESIS; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; LIVER REGENERATION; MALIGNANT TRANSFORMATION; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR PROMOTION;

ANIMALS; CARCINOGENS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; LIVER REGENERATION; MICE; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344;

EID: 68949142885     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02416.x     Document Type: Review

References (57)

1. World Health Organization. Mortality database Accessed 6 February 2009.) Available from: http://www.who.int/whosis/en
2. El-serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 340 : 745 50.
3. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
4. Sherman M. Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Semin Liver Dis 2005 25 : 143 54.
5. Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008 14 : 4300 308.
6. Montalto G, Cervello M, Giannitrapani L et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002 963 : 13 20.
7. Calvisi DS, Thorgeirsson SS. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005 33 : 181 4.
8. Lakhtakia R, Panda SK. Transgenic mouse models and hepatocellular carcinoma: Future prospects. Trop Gastroenterol 2000 21 : 91 4.
9. Narama IK, Iwata H, Nakae D et al. A review of nomenclature and diagnostic criteria for proliferative lesions in the liver of rats by a working group of the Japanese Society of Toxicologic Pathology. J Toxicol Pathol 2003 16 : 1 17.
10. Maronpot RR, Montgomery CA Jr., Boorman GA et al. National toxicology program nomenclature for hepatoproliferative lesions of rats. Toxicol Pathol 1986 14 : 263 73.
11. Eustis SL. The sequential development of cancer: A morphological perspective. Toxicol Lett 1989 49 : 267 81.
12. Ogawa K, Onoe T, Takeuchi M. Spontaneous occurrence of γ-glutamyl transpeptidase-positive hepatocytic foci in 105-week-old Wistar and 72-week-old Fischer 34 male rats. J Natl Cancer Inst 1981 67 : 407 12.
13. Chiaverotti T, Carabeo R, Drinkwater N. Genetic and hormonal regulation of murine hepatocarcinogenesis. Prog Exp Tumor Res 1999 35 : 131 42.
14. Farber E. The pathology of experimental liver cell cancer. In : Cameron HM, Linsell DA, Warwick GP, eds. Liver Cell Cancer. Amsterdam : Elsevier, 1976 243 77.
15. Yokota K, Ogawa K, Mori M et al. Lack of albumin as genotypic marker of preneoplastic analbuminemic rat hepatocytes transplanted within albumin-positive liver. Cancer Res 1988 15 : 387 92.
16. Vesselinovitch SD, Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res 1983 43 : 4253 9.
17. Ogawa K, Solt DB, Farber E. Phenotypic diversity as an early property of putative preneoplastic hepatocytes populations in liver carcinogenesis. Cancer Res 1980 40 : 725 33.
18. Moore MA, Nakagawa N, Satoh K et al. Single GST-P positive liver cells: Putative initiated hepatocytes. Carcinogenesis 1987 8 : 483 6.
19. Suzuki S, Asamoto M, Tsujimura K et al. Specific differences in gene expression profile revealed by cDNA microarray analysis of glutathione S-transferase placental form (GST-P) immunohistochemically positive rat liver foci and surrounding tissue. Carcinogenesis 2004 25 : 439 43.
20. Moto M, Okamura M, Muguruma M et al. Gene expression analysis on the dicyclanil-induced hepatocellular tumors in mice. Toxicol Pathol 2006 34 : 744 51.
21. Kinoshita A, Wanibuchi H, Morimura K et al. Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression. Carcinogenesis 2003 24 : 1389 99.
22. Tatematsu M, Ho RH, Kaku T et al. Studies on the proliferation and fate of oval cells in the liver of rats treated with 2-acetylaminofluorene and partial hepatectomy. Am J Pathol 1984 114 : 418 30.
23. Ogawa K, Minase T, Onoe T. Demonstration of glucose 6-phosphatase activity in the oval cells of rat liver and the significance of the oval cells in azo dye carcinogenesis. Cancer Res 1974 34 : 3379 86.
24. Becker FF. Thioacetamide hepatocarcinogenesis. J Natl Cancer Inst 1983 71 : 553 8.
25. Nakae D. Endogeneous liver carcinogenesis in the rat. Pathol Int 1999 49 : 1028 42.
26. Vesslinovitch SD. Perinatal mouse liver carcinogenesis as a sensitive carcinogenesis model and the role of the sex hormonal environment in tumor development. Prog Clin Biol Res 1990 331 : 53 68.
27. Kaufmann WK, Zhang Y, Kaufman DG. Association between expression of transforming growth factor-α and progression of hepatocellular foci to neoplasms. Carcinogenesis 1992 13 : 1481 3.
28. Kitano M, Ichihara T, Matsuda T et al. Presence of threshold for promoting effects of phenobarbital on diethylnitrosamine-induced hepatic foci in the rat. Carcinogenesis 1998 19 : 1475 80.
29. Tanno S, Ogawa K. Abundant TGFα precursor and EGF receptor expression as a possible mechanism for the preferential growth of carcinogen-induced preneoplastic and neoplastic hepatocytes in rats. Carcinogenesis 1994 15 : 1689 94.
30. Solt DB, Farber E. New principle for the analysis of hepatocarcinogenesis. Nature 1976 263 : 701 6.
31. Breuhahn K, Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 2008 11 : 1690 98.
32. Schirmacher P, Held WA, Yang D et al. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992 52 : 2549 56.
33. Jang HS, Kang KM, Choi BO et al. Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. World J Gastroenterol 2008 14 : 1394 8.
34. Ooasa T, Karasaki H, Kanda H et al. Loss of imprinting of the insulin-like growth factor II gene in mouse hepatocellular carcinoma cell lines. Mol Carcinog 1998 23 : 248 53.
35. Ishizaki T, Yoshie M, Yaginuma Y et al. Loss of Igf2 imprinting in monoclonal mouse hepatic tumor cells is not associated with abnormal methylation patterns for the H19, Igf2, and Kulqt1 differentially methylated regions. J Biol Chem 2003 278 : 6222 8.
36. De La Coste A, Rinagbiki B, Billuart P et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998 95 : 8847 51.
37. Ogawa K, Yamada Y, Kishibe K et al. b-Catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res 1999 59 : 1830 33.
38. Aydinlik H, Nguyen TD, Moennikes O et al. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of b-catenin-mutated mouse liver tumors. Oncogene 2001 20 : 7812 6.
39. Calvisi DF, Factor VM, Loi R et al. Activation of b-catenin during hepatocarcinogenesis in transgenic mouse models: Relationship to phenotype and tumor grade. Cancer Res 2001 61 : 2085 91.
40. Gotoh J, Obata M, Yoshie M et al. Cyclin D1 over-expression correlates with b-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3b and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 2003 24 : 435 42.
41. Harada N, Oshima H, Katoh M et al. Hepatocarcinogenesis in mice with b-catenin and Ha-ras gene mutations. Cancer Res 2004 64 : 48 54.
42. Tanaka H, Yamamoto M, Hashimoto N et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1a as an early change in mouse hepatocarcinogenesis. Cancer Res 2006 66 : 11 263 70.
43. Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Sem Cell. Dev Biol 2008 19 : 329 40.
44. Miyakoshi M, Tanaka H, Hashimoto N et al. Stat3 activation as early change in multi-step hepatocarcingenesis. Proc Am Assoc Cancer Res 2008 49 : 202 3.
45. Yamamoto M, Tamakawa S, Yoshie M et al. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog 2006 45 : 901 13.
46. Ogawa K, Yoshie M, Tamakawa S et al. Possible role of the microenvironment created by neoplastic hepatocytes during hepatic carcinogenesis. Appl Genom Proteom 2003 2 : 135 43.
47. Kishibe K, Yamada Y, Ogawa K. Production of nerve growth factor by mouse hepatocellular carcinoma cells and expression of TrkA in tumor-associated arteries in mice. Gastroenterology 2002 122 : 1978 86.
48. Asai K, Tamakawa S, Yamamoto M et al. Activated hepatic stellate cells overexpress p75NTR after partial hepatectomy and undergo apoptosis on nerve growth factor stimulation. Liver Int 2006 26 : 595 603.
49. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 2009 87 : 2095 147.
50. Nakamura T, Arakaki R, Ichihara A. Inteleukin-1β is a potent growth inhibitor of adult rat hepatocytes in primary culture. Exp Cell Res 1988 179 : 488 97.
51. Yamada Y, Karasaki H, Matsushima K et al. Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab Invest 1999 79 : 1059 67.
52. Zeng ZZ, Higashi S, Kitayama W et al. Genetic resistance to chemical carcinogen-induced proneoplastic hepatic lesions in DRH strain rats. Cancer Res 2000 60 : 2876 81.
53. Higashi K, Denda A, Higashi T, Hiai H. Genetic resistance to chemical hepatocarcinogenesis in the DRH rat strain. Comp Med 2004 54 : 373 7.
54. Imai K, Yamamoto M, Tanaka H et al. Low selection of preneoplastic hepatocytes after treatment with the 2-acetylaminofluorene diet-partial hepatectomy regimen in the liver of hepatocarcinogenesis-resistant DRH strain rats. Oncol Rep 2007 17 : 55 60.
55. Honmo S, Ozaki A, Yamamoto M et al. Low p38 MAPK and JNK activation in cultured hepatocytes of DRH rats; a strain highly resistant to hepatocarcinogenesis. Mol Carcinog 2007 46 : 758 65.
56. Imamura E, Yamamoto M, Miyakoshi M et al. Differential growth capacity between infant and adult mouse hepatocytes in vitro correlates to the cyclin D1 level without relation to oxidative DNA damage. Liver Int 2005 25 : 1036 43.
57. Ogawa K, Mukai S, Onoe T. Effect of aging on proliferative activity of normal and carcinogen-altered hepatocytes in rat liver after a two-thirds partial hepatectomy. Jpn J Cancer Res 1985 76 : 779 84.